RxDoctor Payments DataLook up a doctor →

David Svetich, MD

Colon & Rectal Surgery · Lexington, KYNPI 1669472593

Payments from drug & device makers

$7,792in general payments, 2019–2025

Across 385 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$739
  • Takeda Pharmaceuticals U.S.A., Inc.$494
  • Bristol Myers Squibb$424
  • Ferring Pharmaceuticals Inc.$305
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,786100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,792 in reported general payments places this provider in the 60th percentile of 28 colon & rectal surgery providers in Kentucky.

See all colon & rectal surgery providers in Kentucky

Medicare billing

Part B allowed, 2024
$122,008
Medicare patients
298
Services billed
2,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide11$981,559
ZenpepLipase/Protease/Amylase16$55,233
CreonLipase/Protease/Amylase17$23,469
Pyridostigmine Bromide464$18,484
Budesonide DrBudesonide56$10,224
Colestipol Hcl74$9,230
Vancomycin Hcl16$8,603
LoperamideLoperamide Hcl13$985
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine30$972
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates14$835
Tamsulosin Hcl86$562
Sulfasalazine19$495
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$396
Metronidazole23$249
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$494$981,55911 claims
AbbVieCreon$1,557$23,46917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 colon & rectal surgery providers in Kentucky.

Other colon & rectal surgery in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →